Akorn’s Zatidor generic
This article was originally published in The Tan Sheet
Executive Summary
FDA grants Akorn approval July 27 for its generic version of Novartis' Zatidor OTC ophthalmic solution (ketotifen fumarate 0.025%), the Buffalo Grove, Ill.-based firm announces in a same-day release. The product, which was approved for OTC use by the agency in October 2006, is indicated for up to 12 hours of relief of itchy eyes due to pollen, ragweed, grass, animal hair and dander, Akorn states (1"The Tan Sheet" Oct. 23, 2006, p. 4). The firm estimates Novartis' branded product posted $36 mil. in sales in 2006. The firm plans to launch the product by October, according to the release. Bausch & Lomb has already announced the release of its Zatidor equivalent (2"The Tan Sheet" July 2, 2007, In Brief)...
You may also be interested in...
Novartis Expects Clear Demand For Zaditor Following OTC Switch Approval
Novartis plans to differentiate its antihistamine eye-drop product Zaditor in the OTC market by positioning the drug as a treatment for the cause, not the symptoms, of itchy eyes
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.